Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
TARACTAN is an oral concentrate small-molecule antipsychotic approved in 1967 by Roche. The mechanism of action and specific indications are not currently documented in available data. This legacy product represents a foundational psychiatric therapeutic from the mid-20th century antipsychotic era.
With LOE approaching and minimal Part D commercial data, this legacy product likely operates as a niche or discontinued brand with minimal team resources.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on TARACTAN offers limited career growth and mobility due to its LOE-approaching status and minimal commercial activity. Professionals assigned to this product are typically in maintenance, compliance, or transition roles within legacy brand portfolios.
Worked on TARACTAN at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.